Kymera CLO sells 6,371 shares for tax withholding

Kymera Therapeutics’ chief legal officer automatically sold shares to cover RSU tax withholding, not as a discretionary trade.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. (KYMR) reported that Chief Legal Officer Brian Adams sold a total of 6,371 shares of common stock on September 4, 2026. The company states these sales were required to cover tax withholding obligations upon vesting of restricted stock units and occurred automatically, not at his discretion. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 6,371 shares

Net Sell 3 txns

Insider Adams Brian

Role Chief Legal Officer

Sold 6,371 shs ($744K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,209	$115.55	$140K
Sale	Common Stock F1, F3	3,025	$116.81	$353K
Sale	Common Stock F1, F4	2,137	$117.57	$251K

Holdings After Transaction: Common Stock — 50,254 shares (Direct)

Footnotes (4)

1. F1. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Total shares sold: 6,371 shares Shares sold at $115.55: 1,209 shares Shares sold at $116.81: 3,025 shares +2 more

5 metrics

Total shares sold 6,371 shares Common stock sold on September 4, 2026 to cover tax withholding

Shares sold at $115.55 1,209 shares Common stock sale on September 4, 2026 at weighted average $115.55

Shares sold at $116.81 3,025 shares Common stock sale on September 4, 2026 at weighted average $116.81

Shares sold at $117.57 2,137 shares Common stock sale on September 4, 2026 at weighted average $117.57

Price ranges $115.09–$117.85 per share Ranges of multiple trades underlying the three weighted average sale prices

Key Terms

restricted stock units, tax withholding obligations, weighted average price

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to cover tax withholding obligations in connection with the vesting"

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

What insider transaction did KYMR report for its Chief Legal Officer?

Kymera Therapeutics reported that Chief Legal Officer Brian Adams sold 6,371 shares of common stock on September 4, 2026. The company states the shares were sold to satisfy tax withholding obligations tied to vesting restricted stock units and that the sales were automatic.

At what prices were the KYMR shares sold in this Form 4 filing?

The Form 4 reports weighted average sale prices of $115.55, $116.81, and $117.57 per share. Footnotes state each price reflects multiple trades within narrow ranges between $115.09 and $117.85, with full trade breakdowns available on request.

Were the KYMR insider sales made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as being made under a plan, and the footnotes explain the sales were executed automatically to cover tax withholding on vesting restricted stock units, rather than at the reporting person’s discretion.

Why did Kymera’s Chief Legal Officer sell 6,371 KYMR shares?

The company states the 6,371 shares were required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units. According to the footnote, these sales were automatic and not directed by the reporting person.

How many separate KYMR sale transactions are disclosed in this Form 4?

The Form 4 discloses three non-derivative sale transactions in Kymera Therapeutics common stock on September 4, 2026, totaling 6,371 shares. Each transaction has its own weighted average sale price and price range described in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 06:00 PM Accepted by SEC EDGAR 09/04/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adams Brian

(Last) (First) (Middle)

500 NORTH BEACON STREET

4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		S(1)		1,209	D	$115.55(2)	55,416	D
Common Stock	09/04/2026		S(1)		3,025	D	$116.81(3)	52,391	D
Common Stock	09/04/2026		S(1)		2,137	D	$117.57(4)	50,254	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Bruce Jacobs, as Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)